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FOREWORD
My interest in the field of signal transduction began while I was 
an undergraduate student at the University of London in 1979.  I 
studied the impact of Philip Cohen’s discovery in the early 1970s, 
of phosphorylation and dephosphorylation of proteins involved 
in glucose metabolism. Subsequently I pursued my PhD in 1982 
focussing on the role of proteinases in the epidermal growth factor. 
At that time the signal transduction pathway was a simple linear 
pathway, though now it has exploded into a massive network of 
pathways with numerous proteins involved in the cascade.  The 
1980s, on the other hand, were filled with the excitement of the 
discoveries of tyrosine kinase receptors, tyrosine phosphorylation 
by tumour viruses and viral oncogenes which had counterparts in 
the human body.
Subsequently I left research in the area of signal transduction 
for the following 17 years. Initially, after my PhD,  I took up a 
postdoctoral position at the Department of Cell Biology, Stanford 
School of Medicine, California, in Dr Peter Parham’s laboratory. 
There I acquired skills in molecular biology and conducted many 
experiments in gene cloning as well as DNA sequencing.  My 
colleagues and the research environment at Stanford University were 
a source of great inspiration for me and this enriching experience 
continues to inspire me.  From USA, I moved on to work at the 
Institute of Molecular Biology in Singapore, CSIRO Melbourne, 
and the Burnet Institute (formerly the Macfarlane Burnet Institute), 
where my research involved me in the world of cytokines in 
infectious diseases and vaccines as well as the development of 
diagnostic tests  and vaccines for Hepatitis E.  In 1997, I returned to 
Malaysia and was employed at the Faculty of Medicine and Health 
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Sciences,  Universiti Putra Malaysia, initially to teach the medical 
students Biochemistry and subsequently Virology and Immunology.
Over the last ten years, my research areas at UPM have 
covered the following: (1) elucidation of the aberrations in signal 
transduction pathway in colorectal, breast and nasopharyngeal 
carcinoma; (2)  determination of the cytotoxic effects of purified 
compounds from Malaysian-derived soil bacteria; (3) generation of 
activated cytotoxic T lymphocytes towards adoptive immunotherapy 
for cancer therapy; (4) elucidating the immunomodulatory effects 
of mesenchymal stem cells towards cell-based therapy for cancer 
treatment; and (5) development of diagnostic tests and therapeutics 
in candidiasis and aspergillosis.  All this was accomplished with 
contributions from my graduate students.
I will begin with my story on signal transduction pathways. 
This will be followed by the discovery of natural compounds from 
a soil-derived bacteria, Streptomyces, and then the field of adoptive 
immunotherapy using cytotoxic T lymphocytes.  The ultimate goal 
of this multi-pronged approach is to obtain the ‘magic bullets’ to 
kill cancer cells.  This will involve blocking the appropriate signal 
transduction pathways and enhancing sensitivity to chemotherapy 
with natural compounds. The potential of infusing activated 
cytotoxic T lymphocytes or mesenchymal stem cells needs to be 
further exploited.  Since cancer cells are dynamic, heterogenous 
and undergo mutations in order to keep surviving until they kill the 
host, it is envisaged that this multi-pronged approach holds great 
potential in the fight against this devastating disease. 
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ABSTRACT
Despite continuing intensive research, cancer is still a devastating 
disease with high mortality rates.  However, progress made in 
understanding the behavior of tumour cells has led to advances in 
the creation of ‘magic bullets’ for treating cancer as exemplified 
by imatinib, an inhibitor that targets an oncogenic kinase, namely, 
bcr-abl.  This article will focus on the seminal discoveries made in 
oncogenes, growth factor receptors and tyrosine phosphorylation 
and contributions from my research on signal transduction, adoptive 
immunotherapy and drug discovery.  
Signal transduction is a process whereby a cascade of 
proteins is activated inside the cell causing the cancer cell to grow 
uncontrollably and spread to other parts of the body.  By blocking 
the signals with molecular-targeted drugs, the cancer cell growth 
can be controlled. The success of molecularly-targeted drugs 
depends on the target and knowledge of the signal transduction 
network. Due to the limited information on tumours available in 
Malaysia, we set out to determine the incidence of expression of 
proteins such as the epidermal growth factor receptor (EGFR), 
phosphatidyl-inositol-3-kinase (PI3K), pTEN, Akt and downstream 
targets such as β-catenin, pBAD, pGSK, pmTOR and pFHKR, by 
immunohistochemistry.  This can provide insights into the possible 
mechanism of survival of colorectal, breast and nasopharyngeal 
carcinoma cells.  The contributions of activating mutations such 
as PI3K in colorectal, breast and nasopharyngeal carcinoma were 
also compared.  This approach revealed the potential therapeutic 
targets relevant to our population. 
In the second phase of the research program, we attempted 
to isolate inhibitors of signal transduction from soil-derived 
Actinomycetes. The ability of natural compounds purified from 
extracts of soil-derived Actinomycetes (genus Streptomycetes) 
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to induce apoptosis, cytotoxic and cell cycle effects were also 
measured.  This led to the discovery of the ability to arrest cells 
in the G1 phase in a breast cancer cell line, MCF-7. Further, the 
synergistic effect with a PI3K inhibitor was also revealed.   
Another approach to cancer treatment is adoptive immunotherapy. 
Conditions for the generation of cytotoxic CD8+ T lymphocytes 
with recognition for HER2-peptide specific and Epstein Barr viral 
protein and latent membrane protein-2 (LMP-2) were established 
to obtain cells for treating breast and nasopharyngeal carcinoma 
patients.   The existence of cells with T regulatory cell phenotype 
was detected in breast and nasopharyngeal carcinoma. An alternative 
state of the art approach using mesenchymal stem cells for cancer 
therapy was also attempted. Subsequently, the immunomodulatory 
effects of umbilical mesenchymal stem cells was demonstrated with 
K562, an undifferentiated erythromyeloblastoid leukemia cell line. 
Lastly, the development of molecular diagnostic tests for ten 
species of Candida species was achieved. Monoclonal antibodies 
against Candida glabrata and Aspergillus fumigatus were also 
produced.  
In summary, we have successfully demonstrated the aberrations 
of the signal transduction pathway in primary breast, colorectal 
and nasopharyngeal carcinoma. This study has given us an insight 
into the relevant biomolecules in the cascade.  Results from the 
nasopharyngeal carcinoma tissues revealed that the PI3K/Akt/
mTOR pathway is not a linear pathway.  The potency of the natural 
compound for cancer treatment will need to be tested on animal 
models.  The second approach of harnessing the immune system 
showed promising results.  The effectiveness of the cytotoxic T 
cells and mesenchymal stem cells generated will need to be tested 
on animal models. Thus, further work is warranted to improve 
treatment outcomes for cancer patients.
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BASICS IN MOLECULARLY-TARGETED THERAPIES  
AND CANCER
Introduction
“Discovery consists of seeing what everybody has seen and 
thinking what nobody has thought”
-Albert Szent-Gyorgyi, Hungarian American biochemist-
According to the American Cancer Society, cancer is a group 
of diseases characterized by uncontrolled growth and spread of 
abnormal cells. If the spread is not controlled it can result in death. 
Cell growth and division in normal cells are tightly controlled. 
Cancer cells, on the other hand, have lost their ability to regulate 
their own growth or to respond to normal growth regulatory cues. 
In a paper by Hanahan and Weinberg (2000), which has been cited 
at least  6000 times todate, cancer cells were described as those that 
have acquired the capability to be self-sufficient in growth signals, 
are insensitive to antigrowth signals, can evade apoptosis, have 
unlimited replicative potential, have sustained angiogenesis and 
have the ability to invade tissue and metastasize.  Our understanding 
of the cellular changes that convert normal cells to cancer cells 
have been due to advances in the 1970s and 1980s in the area of 
tumour virology, cell culture, oncogenes, growth factor receptors 
and tyrosine kinases. During the same period, advances in gene 
cloning, DNA sequencing and recombinant DNA technology 
contributed significantly to the progress of oncogene and growth 
factor receptor discovery (Figure 2). Oncogenes are defined as genes 
that contribute to the conversion of normal cells into cancer cells. 
Proto-oncogenes are present in normal cells and when mutated, 
these genes are called oncogenes.    
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A tumour is def ined as an abnormal growth of tissue 
resulting from uncontrolled, progressive multiplication of cells. 
Conventional treatment regimens to eliminate tumours include 
surgery, radiotherapy and/or chemotherapy with cytotoxic drugs 
such as gemcitabine, oxaliplatin, paclitaxel and irinotecan. The 
side effects of chemotherapeutic drugs include nausea, vomiting, 
hair loss and immunosuppression. Further, autologous bone 
marrow transplantation can be used for treatment of leukemias and 
lymphomas. In 1977, tamoxifen, an antagonist of the oestrogen 
receptor, was approved for treatment of breast cancer in USA. 
However, not all breast cancer patients responded to tamoxifen 
and risk of recurrence was not uncommon.  The advances made 
in the 1980s, in molecular and cell biology, provided information 
on the mechanisms that regulate survival or proliferation of the 
tumour cell.  These studies led to innovations in targeted therapies. 
In May 2001, imatinib was approved by the United States Food 
and Drug Administration, for treating chronic myeloid leukemias. 
The cover of the TIME magazine hailed it as the ‘magic bullet’ 
for curing cancer.  Another approach in targeted therapies is the 
application of humanized monoclonal antibodies.  One major 
example is trastuzumab which is used to target the human epidermal 
growth factor receptor (HER)-2 on breast cancer cells. However, 
Cardiac dysfunction was observed in some patients treated with 
trastuzumab.  Thus, the search for  the ‘magic bullets’ continues. 
This review describes the early discoveries of oncogenes, growth 
factor receptors and tyrosine kinases that are of central importance 
to the development of targeted therapies.  The efforts made by my 
research team in dissecting the aberrations of signal transduction 
pathways and inhibitors from natural compounds will be described, 
as well as the current status of cell-based therapies.
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Signal Transduction 
Signal transduction is a process by which a cell responds to a 
stimulus outside the cell resulting in a cellular response and 
alterations in gene expression.  Protein phosphorylation and 
dephosphorylation play key roles in signal transduction. A kinase 
is an enzyme that catalyzes the addition of a phosphoryl group to 
a protein, an event called phosphorylation. Tyrosine kinase adds a 
phosphoryl group to the tyrosine residue of a protein. 
The external stimulus that triggers signal transduction is 
referred to as the ligand if it binds to a protein such as a cell surface 
receptor.  Examples of external stimuli (ligand) include growth 
factors such as the epidermal growth factor (EGF), amino acid 
derivatives such as histamine or adrenaline, steroids, damaged 
DNA or gases such as nitric oxide.  When the ligand binds to the 
receptor, signal transduction is initiated and the cell responds 
accordingly.   Thus, the receptor and cytoplasmic tyrosine kinases 
act as the connecting bridge between extracellular signals in the 
form of ligands and intracellular signaling pathways.
The process involves modification of proteins by tyrosine 
phosphorylation through the protein kinase resulting in changes in 
activity location and association of proteins which are components 
of the signalling process.  A cascade of proteins is phosphorylated 
in the signal transduction pathway.
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Figure 1  The figure above represents a generic signal 
transduction process whereby the steps are: (1) binding of 
the external stimulus (ligand) to the cell surface receptor; (2) 
activated receptor binds to the adaptor molecules such as Ras 
in the cytoplasm; (3) a series of proteins are phosphorylated 
resulting in cellular responses such as apoptosis or promote 
cell survival; and (4) translocation of some proteins to the 
nucleus or activation of transcription factor binding to specific 
DNA sequences resulting in alterations in gene expression 
such as those that increase proliferation,  
differentiation or cell migration.
In reality, a complex biochemically-related network working in 
a concerted fashion is used by regulatory biomolecules to mediate 
signals from the plasma membrane to the  nucleus to cause cellular 
responses such as cell proliferation, apoptosis, differentiation, 
migration and angiogenesis. 
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Milestones in Oncogene and Growth Factor Receptor 
Tyrosine Kinases
The original discovery of the tumour virus that contributes to cancer 
was made by Peyton Rous in 1910 (Rous 1910). He successfully 
transplanted tumours from a Plymouth Rock hen to other chickens. 
Based on the work by Ellerman and Bang (1908), he showed that 
cell-free extracts from the tumour were able to induce solid tumours 
in other chickens (Rous 1911). His discovery was met with suspicion 
because at that time it was believed that cancer was of endogenous 
rather than of infectious origin. By the 1950s, various viruses, as 
listed in Table 1, were shown to cause tumours.  In 1969,  Hueber 
and Todaro  showed that oncogenes from RNA tumour viruses in 
animals could cause cancer when the latent transforming genes were 
activated. Subsequently, the cellular origin of viral src was reported 
by Southern Blot hybridisation of normal avian DNA with a DNA 
probe specific for viral src (Stehelin et al., 1976). The src protein 
was later identified in 1977 (Beemon et al., 1977) and shown to be 
a protein kinase (Collett and Erikson, 1978). In recognition of his 
work, Rous was awarded the Nobel Prize in 1966, 56 years after 
the discovery of the Rous sarcoma virus.  
In the 1950s, Levi-Montalcini and Stanley Cohen purified the 
nerve growth factor from large quantities of snake venom and mouse 
salivary gland extracts.  In 1978, Cohen identified the epidermal 
growth factor receptor (EGFR) and associated tyrosine kinase 
activity. He also proposed that the phosphorylation of membrane 
components and associated proteins might be crucial in the 
generation of intracellular signals that regulate proliferation (Ushiro 
and Cohen 1980).   In 1980, Hunter and Sefton discovered that the 
transforming protein of the Rous sarcoma tumour virus, v-src, had 
tyrosine phosphorylation activity.  This milestone discovery linked 
deregulated protein tyrosine phosphorylation to tumorigenesis.  In 
❚❘❘ 8
Are there “ Magic Bullets” for Cancer Therapy?
1980, Michael Bishop and Harold Varmus raised the question on 
whether the oncogenes that initiate signal transduction pathways 
through tyrosine phosphorylation could also induce cancer.   In 
recognition of their work, Levi-Montalcini and Stanley Cohen 
shared the 1986 Nobel Prize for Medicine and Physiology, while 
Michael Bishop and Harold Varmus were awarded the Nobel Prize 
in 1989.
Figure 2  Key milestones in the discovery of oncogenes, 
tumour suppressors, tyrosine phosphorylation, molecular 
targeted drugs and recombinant DNA technology
The discovery of the growth factor receptor tyrosine kinases 
(RTKs), tyrosine phosphorylation by tumour viruses together with 
the finding that animal retroviral oncogenes are of cellular origin, led 
to the concept that oncogenes initiating signaling pathways through 
tyrosine phosphorylation induced human cancer. A review of the 
timelines of these discoveries has been published (Gschwind et al., 
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2004).  Table 1 shows the animal viruses with ability to transform 
cells and associated oncogenes. 
Table 1  Animal viruses with oncogenic activity
Oncogene Retrovirus Origin Oncogene product 
abl Abelson murine 
leukemia virus 
mouse Protein tyrosine kinase 
Erb-B A v i a n 
erythroblastosis 
virus 
chicken Truncated EGF receptor 
src Rous sarcoma 
virus 
chicken Protein tyrosine kinase 
fos Murine sarcoma 
virus 
mouse Transcription factor 
AP-1 complexes with 
fos 
jun Avian sarcoma 
virus 
chicken Transcription factor 
AP-1 complexes with 
jun
sis Simian sarcoma 
virus 
monkey Truncated PDGF (b 
chain) 
myc Myelocytoma 
virus 29 
chicken DNA binding protein 
fes Feline sarcoma 
virus 
cat Protein tyrosine kinase 
As the cDNA cloning technologies improved in the early 1980s, 
the EGF receptor and oncogenes such as Ras (Shih and Weinberg, 
1982), sis (Doolittle et al., 1983; Waterfield et al., 1983), v-erbB 
(Debuire et al., 1984) and Akt (Staal, 1987) were cloned. Ras was 
shown to mediate transformation by Src signaling (Smith et al., 
1986) and Ras/MAPK and PI3K were parallel signaling pathways 
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initiated for the transformation process  (Pineul and Martin, 
1999). Homologues of cellular proto-oncogenes and growth factor 
receptors were also discovered. Meanwhile, the Epidermal growth 
factor receptor was found to have sequence homology to a known 
avian erythroblastosis virus onocgene, v-erbB.  Other growth 
factor receptors with homology to oncogenes include the human 
epidermal growth factor receptor-2 (c-erb2),  steel factor receptor 
(c-kit), insulin growth factor-1 (c-ros), fibroblast growth factor 
receptor (fig), colony stimulating factor-1 receptor (c-fms) and the 
neurotrophic growth factor receptor (trk).  
The seminal discovery by Hunter and Sefton (1980) supported 
the idea that small changes in the regulatory pathway had a great 
impact in conversion of a normal cell into a cancer cell, triggered 
by a burst of activity in signal transduction.  A number of papers in 
the area of signal transduction started to appear in the late 1980s. 
The figures show that there was a 5-fold increase from 1990-1995 
(approximately 500 in 1990 as compared to 2500 in 1995).  From 
1995, the number of papers published continued to rise steadily with 
3000 and 3500 publications in the year 2000 and 2005, respectively. 
A total of 48,377 papers were published from 1977 to 2007, of 
which 11,211 were reviews. This indicates that signal transduction 
is an area of intensive research.  Interestingly, the outcome of 
this research has been translated into clinical applications. As of 
2009, there are now 16 drugs targeting protein kinases in signal 
transduction pathways and 153 protein kinase inhibitors undergoing 
clinical trials, with 23 in phase III clinical trials.  Examples of these 
molecularly-targeted drugs are trastuzumab, Gleevec, gefitinib, 
cetuximab and bevacizumab. The timeline for their approval and 
applications are as shown in Figure 2 and Table 3.
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Figure 3  The figures above  shows the number of papers 
containing the specific term “signal transduction” published 
in the MEDLINE database from 1977 until 2007 (http://www.
wikimediafoundation.org/wiki)
Why Do Cancers Arise?
Over the past 50 years, the paradigm in cancer research is that 
cancer begins with a single mutation in a somatic cell followed 
by successive mutations. Activating mutations of oncogenes or 
deactivation of tumour suppressor genes occur resulting in loss of 
control of the cell cycle and escape from the normal biochemical 
systems that regulate the balance between apoptosis and survival. 
Cancer cells achieve independence from growth signals by 
constitutively overexpressing growth factor receptors, activating 
downstream signal molecules or possessing activating mutations. 
In addition, gene amplifications (eg.cyclin D amplification) or 
chromosomal translocations (eg. Abl-bcr in acute lymphoblastoid 
leukemia) can cause deregulation of the signal transduction pathway 
resulting in induction of cell proliferation independent of growth 
receptor activation.
Under physiological conditions, cell proliferation is induced 
by growth factors such as the epidermal growth factor (EGF).  In 
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the 1980s,  overexpression of EGFR and deregulated signalling 
were described in many cancers (Gullick 1991).   Downstream of 
the growth factor receptor, the common transduction proteins are 
RAS and phosphatidylinositol-3-kinase (PI3K).  RAS was first 
identified as the cellular homologue of the viral oncogene of the 
transforming retroviruses ( Shih and Weinberg, 1982).  One of 
the best described signaling pathway downstream of the receptor 
tyrosine kinase is the RAS/RAF/MEK/ERK pathway (Chang  et 
al. 2003).  The signaling cascade downstream from growth factor 
receptors (RAS, RAF, MEK, ERK)  can directly or indirectly (by 
the induction of survival signals) inhibit cell death.
Figure 4  A schematic representation of the RAS/RAF/MEK/
ERK pathway activated by the epidermal growth factor (EGF)
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The human epidermal growth factor receptor 2 (HER2), also 
known as c-erbB2 or neu, is a tyrosine kinase receptor.  The HER2 
gene was reported to be overamplified in 20-30% of breast cancers 
and is correlated with relapse and poor survival (Slamon et al., 
1987).  HER2 overexpression has also been reported in colon, 
prostate, ovarian and pancreatic cancers.  Akt  can be activated by 
HER2 overexpression in transformed cells (Yu et al., 1998).   Akt1, 
a serine/threonine protein kinase was first discovered as the human 
homologue of a viral oncogene from thymomas in AKR  mice (Staal 
1987). Akt1 was shown to be amplified in gastric adenocarcinoma 
(Staal 1987).   In humans, Akt2  gene amplification has been 
reported  in ovarian, cervical, pancreatic and non-Hodgkin’s 
lymphoma (1992).  Figure 5 below is a schematic representation 
of the HER2 signalling pathway involving RAS/RAF/MEK/ERK 
and PI3K/Akt pathways.
Figure 5  A simple representation of the signal transduction 
pathway activated by HER2 and the downstream effects.
❚❘❘ 14
Are there “ Magic Bullets” for Cancer Therapy?
Another major pathway turned on during neoplasia is the 
phosphoinositide 3-kinase (PI3K) pathway.  PI3K is a lipid kinase 
that regulates  a host of cellular functions, including proliferation, 
survival, shape and mobility,  which play a critical role in facilitating 
the transformation of a cell into a malignant cell.  PI3K was found 
to be associated with EGFR signaling (Bjorge et al., 1990).  
Activation of the receptor tyrosine kinase, eg. EGFR, by ligands 
such as EGF results in the autophosphorylation of the receptor 
which is recognized by phosphoinositide-3-kinase, abbreviated as 
PI3K.  Figure 6 shows activated PI3K catalyses of the turnover of 
the phospholipids resulting in the production of the PIP3, which 
is essential for the recruitment of AKT to the plasma membrane. 
Akt is then phosphorylated at two sites. Phosphorylation of these 
two sites can be detected by antibodies specific to the two residues, 
i.e. Thr 308 and Ser437. Activated Akt phosphorylates a number 
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of proteins, such as BAD, resulting in inhibition of apoptosis and 
stimulation of cell proliferation and growth. pTEN is a phosphatase 
that shuts off PI3K/Akt signaling.
Figure 6 is a schematic representation of the PI3K/Akt signaling 
pathway. Akt is a serine threonine protein kinase.  Activated Akt 
phosphorylates many cellular proteins, such as BAD, FHKR and 
mTOR,  resulting in resistance to apoptosis, stimulation of cell 
growth and dysregulation of the cell cycle.  Activation of Akt can 
be prevented by a phosphatase, namely, pTEN.
Table 2  Functions of  APC, Akt and downstream targets
Biomolecules Functions
APC Tumor suppressor gene; regulates the level of 
β-catenin; mutations in mutation cluster region (nt. 
3000-4800) represents ~ 60% of somatic mutations 
in CRC ( Miyoshi et al., 1992)
β-catenin Binds with LEF/TCF transcriptional factor and 
transactivates downstream target genes; mutations 
in exon 3 have been detected in  colorectal cancers 
p-Akt (Thr308) Phosphorylation of Akt at Thr308 in the activation 
loop, activates PI3K/Akt signaling pathway. 
Expression of p-Akt (Thr308) in colorectal cancer 
was unknown when we commenced our research 
project
p-Akt (Ser473) Phosphorylation of Akt at Ser473 within its 
C-terminus activates PI3K/Akt signaling pathway. 
Expression of p-Akt (Ser473) in colorectal cancer 
has been previously reported (Roy et al., 2002)
p - B A D 
(Ser136)
pro-apoptotic member of Bcl-2 family; downstream 
target of PI3K/Akt pathway; phosphorylation of 
BAD at Ser136 by Akt inhibits BAD mediated 
apoptosis (Datta et al., 1997)
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p-GSK3β Downstream target of PI3K/Akt pathway; important 
in the regulation of β-catenin stability 
FHKR FHKR belongs to the FOXO Forkhead transcription 
factor family.  It promotes transcription of pro-
apoptotic genes such as FasL and Bim. Increased 
Akt activity leads to export of the forkhead 
transcription factor, FHKR from the nucleus to the 
cytoplasm, thus, preventing FHKR from promoting 
expression of the pro-apoptotic genes.
mTOR A  serine/threonine kinase  that serves as a 
molecular sensor that regulates protein synthesis 
based on the availabillty of nutrients
P70S6K Regulator of protein translation; phosphorylates 
ribosomal protein S6 to increase translation of 
messenger RNAs; downstream target of mTOR
Why Study Signal Transduction?
Deregulated signal transduction leads to aberrant cellular behavior 
and, as a consequence, can induce or contribute to various 
disorders such as cancer. Examples of aberrant cellular behaviour 
include increased proliferative potential, sustained angiogenesis 
and inhibition of apoptosis. Hence, understanding the signalling 
cascades has contributed to the numerous molecular targets for 
cancer treatment. After nearly 30 years of intensive research, one 
of the most exciting developments in cancer research has been 
the clinical validation of molecularly targeted drugs that inhibit 
the action of tyrosine kinases.  These molecularly targeted drugs, 
which include trastuzumab (an antibody against human epidermal 
growth receptor-2), bevacizumab (an antibody against the 
vascular endothelial growth factor), cetuximab and panitumumab, 
cont. Table 2
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(antibodies against the epidermal growth factor receptor) and 
imatinib ( a small molecule targeting the abl-bcr kinase), which 
are designed to target signaling pathways hold promise in treating 
human diseases. Their targets are usually proteins that play a role 
in malignant transformation or normal receptors or signalling 
proteins that regulate apoptosis or cell cycle. Blocking the action 
of these proteins arrests uncontrolled growth  and ultimately leads 
to the death of the tumour cell. VEGF is a critical growth factor for 
angiogenesis which is a process that allows the tumour to grow and 
recruit blood vessels in order to spread to other parts of the body. 
Thus, blocking VEGFR activity can inhibit angiogenesis. 
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Figure 7 illustrates the sites targeted by molecularly-targeted 
drugs. Monoclonal antibodies that are antagonists of EGFR, HER2 
and VEGFR include cetuximab, trastuzumab and bevacizumab, 
respectively.   Erlotinib and sunitinib are small molecule tyrosine 
kinase inhibitors of  EGFR and VEGF.  These small molecules block 
the ATP pocket of the receptor, thereby inhibiting phosphorylation 
and downstream signal transduction. Sorafenib inhibits the tyrosine 
kinase activity of PDGF and raf has been used in treatment of 
advanced renal cancer.  Further, Oral mTOR rapamycin analogues, 
everolimus and temsirolimus have displayed encouraging 
antitumour activity.
Figure 7 shows examples of chemicals or drugs known to act 
on specific proteins of the Ras/Raf/MEK/ERK and PI3K/Akt/
mTOR signal transduction pathways. Akt is an indirect regulator 
of mTOR through phosphorylation and inactivation of tuberin 
(TSC2) complex
Table 3  Examples of molecularly-targeted drugs and their applications
Cancer Drug Targeted molecule
Breast Trastuzumab HER-2
B cell lymphoma Retuximab CD20
Colon, lung Cetuximab, gefitinib 
(TK inhibitor)
EFGR
Colorectal Bevacizumab VEGF
CML, GIST, DFSP Imatinib (Glivec) BCR-ABL, c-kit, 
PDGFRB
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Imatinib deserves a special mention as it was considered the 
‘magic bullet’ for the treatment of chronic myeloid leukemia with 
bcr-abl fusion protein (Druker et al., 2001). The bcr/abl fusion gene 
is formed when the  c-abl tyrosine kinase gene on chromosome 9 
is translocated to chromosome 22 and fused with part of the bcr 
gene on that chromosome. The resulting hybrid chromosome, 
the Philadelphia chromosome, encodes a new protein called Bcr/
Abl. This new protein has increased kinase activity and drives 
proliferation causing transformation.  In general, these specific 
inhibitors were expected to have less side effects than conventional 
chemotherapeutic drugs and have improved efficacy and selectivity 
of cancer treatment.  However, they were found  to be more complex 
and some extent of Side effects were also observed.  Efficacy 
required appropriate selection of patients based on the presence of 
targeted molecules and problems of intrinsic drug resistance was 
common.  Thus, understanding the interactions of the signaling 
molecules is of central importance in order to translate the use 
of these specific inhibitors to clinical applications.  However, the 
ability of the cancer cell to develop drug resistance and to constantly 
undergo  mutations or use alternative signaling pathways should 
be noted.  Thus it will continue to be a challenge for clinical 
management. Consequently, it necessary to identify the appropriate 
biomarkers that can be used to accurately assess and individualise 
therapy.
Cancer Incidence in Malaysia
According to the Second Report of the National Cancer Registry 
2003 (Lim and Halimah, 2004) the ten leading types of cancer 
amongst males in Peninsular Malaysia were lung, nasopharynx, 
colon, leukemia, rectum, prostate, stomach, lymphoma, skin and 
liver cancers. Amongst females, the ten leading cancers were breast, 
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cervical, colon, rectum, ovary, leukemia, lung, stomach and other 
skin cancers. 
In Malaysia, the incidence of the different types of cancer 
differs between races.  In Chinese men, nasopharyngeal cancer 
is the second common cancer, while in Malay men, it only ranks 
sixth. The top three most common cancers among Malay men are 
lung, leukaemia and rectal cancer. For Malay women, cancer of the 
breast, cervix and leukaemia are the most common. 
The top three most common cancers in Chinese men are lung, 
nasopharynx and colon cancer. In Chinese women, breast, cervical 
and colon cancer are the most common. For Indian men, cancer 
of the stomach, prostate and leukaemia are the most common, in 
contrast to breast, cervical and oral cancers among Indian women. 
In Malaysia, colorectal cancer is the third most common type of 
cancer. The age-standardized incidence rates for colon cancer were 
13.9 and 11.2 per 100,000 persons, for men and women respectively; 
The age-standardized incidence rates for rectum cancer were 11.7 
and 6.7 per 100,000 persons for men and women respectively. 
In United States, colorectal cancer is ranked fourth in overall 
frequency and second in terms of cancer mortality. The age-
standardized incidence rates were 30.68 and 40.56 per 100,000 
persons for women and men respectively in year 2000. In the 
European Union, the age-standardized incidence rates was 29.36 per 
100,000 persons for both sexes (Parkin et al., 2001).  Thus, higher 
incidence rates of colorectal cancers were recorded for United States 
and European Union.
The annual incidence of new cases of cancer in Malaysia has 
been estimated to be 30,000. In 2002, 4337 cases of breast cancer 
were reported to the National Cancer Registry with an incidence 
rate of 52.8 per 100,000 and accounting for 30.4% of all diagnosed 
malignancies among Malaysian women.  It has been estimated 
that one in 9 Malaysian women has a chance of developing breast 
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cancer. Breast cancer incidence in Malaysia is intermediate between 
the rates of industrialized countries like the US, 91/100,000 and 
developing countries like India, 19/100,000 (Omar and Yip, 2005).
ELUCIDATION OF WNT AND PI3K/AKT PATHWAYS 
IN COLORECTAL, BREAST AND NASOPHARYNGEAL 
CARCINOMA
When we commenced on this research in 2002, limited studies had 
previously been conducted to determine the aberrations of signal 
transduction in tumours among patients in Malaysia.  We set out 
to determine the relevance of Wnt signalling in hepatocellular 
carcinoma and colorectal cancer and then PI3K/Akt pathways in 
breast, colorectal and nasopharyngeal carcinoma.  The relationships 
between the biomolecules in these pathways were determined where 
some of the questions addressed were:
i) Is there a relationship between Wnt and the Akt pathway in 
colorectal cancer?
ii) Is Akt activated in breast cancer and is there a relationship 
between the oestrogen receptor and HER2 positivity?
iii) Is PI3K/Akt activated in nasopharyngeal carcinoma?
In addition, mutations in PI3K and pTEN genes were also 
determined to elucidate the mechanism of oncogenicity in each 
type of cancer.  
APC, Beta-Catenin, pAkt and COX-2 Expression in 
Colorectal Cancer
APC (adenomatous polyposis coli) is a well-known tumour 
suppressor (Kinzler and Vogelstein, 1996) found to be mutated in 
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80% of sporadic colorectal cancers.  Immunohistochemical staining 
with an antibody to the  C-terminus of  APC revealed that only 24 /47 
(51.1%) of colorectal carcinoma tissue and 40/40 adjacent normal 
tissue were immunoreactive to this antibody [p< 0.001 (Mann-
Whitney’s test)].  The lack of immunoreactivity could be explained 
by the mutations of APC that resulted in a premature stop codon. 
A sampling of 11 tumours showed that 5/11 (50%) of the tumours 
harboured the mutations that resulted in the premature stop codon.
Figure 8  An electrophoregram showing the sequence of the 
partial APC gene.  A heterozygous genotype of APC where 
TCA= serine or TGA=stop codon (N= G or C) is as indicated 
by the arrow shown.
The accumulation of β-catenin is an indicator of the activation 
of Wnt signalling. Majority of  tumour cases (97%) express nuclear 
β-catenin, suggesting that strategies to block nuclear β-catenin 
accumulation is likely to be a useful therapeutic strategy. Our 
published data also showed that phosphorylation of Akt was detected 
in 63% of tumours (Ser 473=27% , Thr 308=16% , both =20%) 
(Khor et al., 2004).  Accumulation of cytoplasmic β-catenin was 
also detected in hepatocellular carcinoma (Ban et al., 2003; Ban 
et al., 2004). Further, COX-2 was overexpressed in 80% of CRC 
cases (Hong et al., 2004).  COX-2 inhibitors have been shown to 
reduce mortality by 40-50% and reduce the number of intestinal 
polyps(Taketo, 1998). In conclusion, our study revealed that 
23 ❘❘❚ 
Seow Heng Fong
strategies to block accumulation of β-catenin, phosphorylation of 
Akt and expression of COX-2 are likely to be useful in colorectal 
cancer treatment.
Akt Activation in Breast Carcinoma
Surgery, radiotherapy and chemotherapy remain the treatments 
of choice for breast cancer patients.  An overview of the history 
of chemotherapy (Chabner and Roberts, 2005) and interesting 
developments in breast cancer treatment is summarized in the table 
below (Table 4).
Table 4  History of chemotherapy
Year Drugs
1946 Mustine was used for non-Hodgkin’s lymphoma
1958 Methothrexate for choriocarcinoma; vinca alkaloids 
and antioestrogenic action of  MER-25 was discovered
Late 1970s Successful development of tamoxifen
Several clinical trials with combination chemotherapy 
[CMF (cyclophosphamide, methotrexate, fluorouracil), 
FAC (fluorouracil, adriamycin, cyclophosphamide), 
AC (cyclophosphamide, doxorubicin)] were conducted
1970s-1990s Discovery of anthracylines (topoisomerase II 
inhibitor),   camptohecins,  fluorouracil, cisplatin
1987 Paclitaxel (Taxol) found to be effective for  ovarian 
cancer
1990s Clinical trials with aromatase inhibitors were 
conducted
1997 Trastuzumab approved by US FDA
1999 Docetaxel was the reference agent for treating 
metastatic breast cancer
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For decades, tamoxifen was the most important hormonal agent 
for treatment of breast cancer.  It significantly reduces the risk of 
recurrence and death.  Further, Aromatase inhibitors were found 
to be useful for postmenopausal women. In 1997, trastuzumab, a 
monoclonal antibody to the human epidermal growth factor receptor 
2 present on the plasma membrane of  cells, was approved by the 
US FDA. Tamoxifen and trastuzumab caused a lot of excitement 
as they were thought to be the ‘magic bullets’ for breast cancer 
treatment.  It has since been established that the existence of the 
oestrogen receptor and HER2 serve as basic markers for predicting 
drug response. However, drug resistance remains a problem and 
recurrence of the disease can still occur.  One of the proposed 
mechanisms of drug resistance is the activation of Akt (Clark et 
al., 2002).
Akt is activated by many receptor-stimulated pathways involved 
in breast cancer, including ERa, IGF-IR, epidermal growth factor 
receptor and erbB2 (Clark, et al., 2002).   In vitro studies show that 
activated PI3K catalyzes the production of phosphatidylinositol-
3,4,5-triphosphate (PIP
3
) which is essential for the phosphorylation 
of Akt at Ser473 and Thr308.  Activated Akt then phosphorylates 
many cellular proteins resulting in diverse cellular processes which 
are critical for tumorigenesis such as cell proliferation and survival. 
p-Akt is a powerful promoter of cell survival as it antagonises the 
components of the apoptotic cascade such as the Bcl-2 associated 
death domain (BAD) protein. Akt is also implicated in angiogenesis 
and metastasis which are the two important processes in cancer 
development. Thus, it is not surprising that frequent activation of 
Akt occurs in a wide spectrum of cancers such as prostate, breast 
and ovarian carcinomas.    In vitro studies suggest that the PI3K/
Akt pathway is transduced when the ERa and HER2 are activated 
(Clark et al., 2002).  
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We addressed the question of whether Akt is activated in our 
breast cancer samples and whether  Akt activation correlates with 
ER positivity and c-erbB2 expression. Further, we determined 
the incidence of Akt phosphorylation in breast tumours and the 
relationship between the expression of ER-α, ER-β, HER2, Ki-
67 and phosphorylated Bcl-2 associated death domain (p-BAD). 
Immunohistochemical staining was performed to detect these 
molecules on 43 paraffin-embedded breast tumour tissues with 
commercially available antibodies.  Eighteen (41.9%), 3(7.0%), 23 
(53.5%), 35 (81.4%), 21 (48.8%), 29 (67.4%), and 34 (81.0%) of 
the breast tumours were positive for nuclear ER-α, nuclear ER-β, 
membranous HER2, p-Akt (Thr308), p-Akt (Ser473), p-BAD and 
Ki-67, respectively. The p-Akt (Ser473) correlated with increased 
levels of p-BAD (Ser136) (p=0.012). Cytoplasmic localization 
p-Akt T308 staining was found to be significant in tumour tissues 
35/43 (81.4%) positive (p<0.001).  BAD is phosphorylated and 
inactivated by p-Akt resulting in inhibition of apoptosis tumor 
cells proliferating inappropriately without compensatory apoptosis 
(p = 0.006, r = 0.366).  Correlation analysis revealed that c-erbB2 
signalling could lead to  activation of Akt via  phosphorylation of 
Akt T308 (p = 0.014, r = 0.0366).  To summarise,   Akt activation 
is independent of  oestrogen receptor status and overexpression of 
p-AktT308 correlated with c-erbB2.  
The significance of our study is in that it showed that Akt is 
likely to be a relevant target for breast cancer drug discoveries (Seow 
et al., 2009). Our study does not support the simple model of linear 
ERa/PI3K/Akt pathway in breast cancer.  This data differs from that 
observed with breast cancer cell lines (Clark et al., 2002). Further 
studies will be required to determine the alternative signaling 
pathway utilized by ERa positive breast tumours.
❚❘❘ 26
Are there “ Magic Bullets” for Cancer Therapy?
Aberrant PI3K/Akt of  Signal Transduction Pathway in  
Nasopharyngeal Carcinoma
Epidermal growth factor receptor (EGFR) is a tyrosine kinase 
receptor.  Upon binding of EGF, EGFR initiates signal transduction 
cascades that promote cell division, migration and angiogenesis, and 
inhibits apoptosis.  EGFR is abnormally expressed and activated in 
cancer cells in many tumor types such as breast and colon cancers. 
However, it was unknown whether EGFR is abnormally expressed 
in nasopharyngeal carcinoma.
The objectives of our study were: (i) to elucidate the expression 
rate of pEGFR and the downstream targets, namely, pAkt, 
pBAD, pFKHR, pGSK-3β, p-mTOR  in NPC and non-malignant 
nasopharyngeal tissue specimens; (ii) to determine the relationship 
between these biomolecules; and (iii) to determine whether PI3KCA 
mutations  contribute to  aberrations of the  PI3K/Akt pathway in 
NPC 
Immunohistochemical staining results suggest that the 
activation of the PI3K/Akt pathway is mainly contributed by 
activation of epidermal growth factor receptor (EGFR) rather than 
c-erbB2(HER-2). Forty-one per cent (26/64) of NPC expressed 
the phosphorylated form of EGFR.  EGFR phosphorylation 
correlated with phosphorylation of Akt at Thr308 but not Ser 473. 
Phosphorylation of Akt was positively correlated with phospo-BAD 
(p=0.004), p-FKHR (p=0.001) and Ki-67(p=0.004). No correlation 
was found between phosphorylation of Akt and phosphorylation 
of mTOR and GSK-3β (Yip et al., 2008). Our results suggest 
that the pathogenesis of NPC is more complicated than the linear 
model of the PI3K/Akt/mTOR pathway and that phosphorylation 
of mTOR and GSK-3β occurs via other pathways. Over the last 
few years there have been advances in the use of monoclonal 
antibody to EGFR such as cetuximab for treating non-small lung 
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and colorectal cancers. Immunohistochemical staining to evaluate 
EGFR protein levels is a convenient method for analyzing clinical 
samples.  However, studies show that there is a lack of correlation 
between EGFR overexpression and response to cetuximab (Chung 
et al. 2005;  Scartozzi et al. 2004).  This could be explained by the 
possiblilty of there being downstream signals which are activated 
by other pathways or oncogene mutations such as K-ras mutations 
(ref).  Thus, the clinical benefit of drugs that target EGFR for 
nasopharyngeal carcinoma patients is unclear at this stage. Further 
investigation of the other possible EGFR downstream signals needs 
to be identified in nasopharyngeal carcinoma.
To further understand the mechanisms in aberrations of the 
PI3K signal transduction pathway, the somatic mutations of the 
PIK3CA p110α gene were examined. PIK3CA mutations have been 
frequently found in various human cancers. Most of these mutations 
are clustered in exon 9 (helical domain) and exon 20 (kinase 
domain).  By using PCR with DNA extracted from tumour tissues 
followed by DNA sequencing, no “hotspot” mutations of PIK3CA 
were detected in 25 of our nasopharyngeal carcinoma tissues.  In 
parallel, mutations of breast carcinoma tissues were also studied. 
Six out of 20 (30%) of our breast carcinoma tissues were found to 
harbour PI3KCA mutations (Leong et al., 2009).  Further studies on 
elucidation of the PIK3CA gene copy number and the role of mTOR 
in NPC is currently being investigated. These studies have important 
implications in the selection of currently available targeted drugs 
and future development of molecularly-targeted therapies.
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ANTICANCER EFFECTS OF PURIFIED COMPOUNDS 
FROM SOIL-DERIVED ACTINOMYCETES  
(GENUS STREPTOMYCES)
Introduction
The discovery of new drugs targeted at specific molecules of the signal 
transduction pathway is a ‘hot’ field of research. These molecularly 
targeted drugs may have fewer side effects and thus, may be useful 
alternatives. Secondary metabolites, especially from actinomycetes 
such as Streptomyces, may be among the most important sources 
for novel anti-cancer agents. Microbes have a good history of 
being the source of useful drugs, as exemplified by antibiotics 
such as  penicillin or kanamycin and the immunosuppressive drug, 
tacrolimus.  Among others, an antifungal agent, Staurosporine, 
produced by the actinomycete Saccharothrix aerocolonigenes, was 
found to be effective in inhibiting PKC (protein kinase C); and the 
synthetic analogue, UCN-01 (7-hydroxystaurosporine) was found to 
block the cell cycle (Cohen,  2002).  The use of microbes as source 
of drugs is more advantageous than the use of plants as harvesting 
of plants destroys the environment and at least another 10 years 
will be required to use synthetic biology to produce large amounts 
of material for clinical trials.
Elucidation of  the Mode of  Action of  Compounds from the 
H7372 Strain      
We have been successful in identifying a  strain of  Actinomycetes 
(genus Streptomyces) that can kill cancer cell lines in vitro. These 
extracts have been screened using the yeast hybrid system and were 
found to interfere with Ras-Raf interaction. The results have been 
presented (Lai et al., 2009).
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Figure 9  (a) Growth of strain H7372 on a broth culture plate 
(b) A representative picture showing the mangrove swamp 
where the actinomycetes H7372 was collected.
We were able to detect the presence of  inhibitors from 
actinomycetes, strain H7372, in nasopharyngeal, colon and breast 
cancer cell lines.  Preliminary results indicated that the crude 
extracts could induce apoptosis of a breast cancer cell line and 
reduce the activation of the Akt pathway. We  hypothesize that 
inhibition of the Ras pathway by H7372 will also inhibit other 
signal transduction pathways such as the phosphoinositide-3-kinase 
(PI3K)/Akt pathway, resulting in anti-proliferation and apoptosis 
(ie. death of the tumour cell).  Since there is cross-talk between the 
signal transduction pathways and their network, the compound could 
alter multiple oncogenic pathways. This is advantageous provided 
they do not perturb normal cells. Drug companies are making 
active efforts to discover drugs of this nature. Information on the 
precise targets of the drug is important to ensure that no serious 
side-effects are exerted by these new drugs. Thus, the discovery of 
new compounds is essential for the development of new drugs or 
biologicals.
(a) (b)
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The research approach uses cancer cell lines to test their 
responses to the fractionated extracts containing the antitumour 
active compound. The viability of the cell lines in response to the 
fractions are tested using the MTT assay.  Todate, we have identified 
a compound from a soil-derived bacteria, namely, Streptomyces, 
which has the ability to reduce the viability of a number of cancer 
cell lines such as the MCF-7(breast), TWO-6 (nasopharyngeal), 
HT-29 (colon), liver (HepG2), prostate (PC3), and cervical(HeLa) 
cancer cell lines (Yip et al., 2010). Effects on the cell cycle and 
protein expression were determined by flow cytometry and Western 
Blotting, respectively (Yip et al., 2010). We will also determine 
whether the active fraction can exert synergistic effects with 
other molecularly-targeted drugs such as the antioestrogen drugs, 
tamoxifen, the c-erbB2 inhibitor (trastuzumab) and the epidermal 
growth factor (cetuximab). Resistance to commercially available 
drugs is a problem. Thus, the mode of action of the combination 
of our microbial-derived fraction and the commercial drugs will be 
determined and this could give better insight into the mechanisms 
of drug antagonism and how to overcome it. To summarise, we have 
conducted  a fundamental study on the action of the active fraction 
with and without a combination of commercially available drugs. 
A glycogen-synthase-3-kinase inhibitor was also discovered from 
another strain of Streptomyces (Cheenpracha et al., 2009).
Conventional chemotherapy has long been thought to be 
cytotoxic to both tumour and normal cells.  However, recent evidence 
shows that these cytotoxic drugs can defeat immunosuppression 
and increase the efficacy of active immunotherapy.  A number 
of studies performed more than 20 years ago showed that 
cyclophophosphamide, a cytotoxic drug, when given before a 
cancer vaccine, allowed more effective activation of antitumour 
immunity.  It was thus hypothesized that this could be due to the 
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inhibition of immunosuppressor cells.  However, it was not until 
the late 1990s that the existence of these suppressor cells came 
to light when the identification and isolation of T regulatory cells 
was reported (Sakaguchi et al., 1995).  These T regulatory cells 
have been found to be sensitive to cyclophosphamide (Ghiringhelli 
et al., 2004). We are currently studying whether the compounds 
isolated from Streptomyces (genera Actinomycetes) have an effect 
on immunosuppression.  
GENERATION OF CYTOTOXIC T LYMPHOCYTES FOR 
IMMUNOTHERAPY IN BREAST AND  
NASOPHARYNGEAL CARCINOMA
Introduction
Cytotoxic T lymphocytes (CTLs) are lymphocytes that kill other 
cells, virally infected cells, allografts or tumour cells.   Each CTL 
has a unique T cell receptor (TCR) that is specific to a particular 
target antigenic peptide bound to a Major Histocompatibility 
Complex (MHC) Class I protein on the surface of a tumour cell, 
as depicted in Figure 10. The engagement of the TCR by a MHC/
peptide complex on the target cell triggers the CTL effector 
functions and can result in destruction of the target cell. CTLs 
have cytoplasmic granules that contain the proteins perforin and 
granzymes. When the CTL binds to its target, the contents of the 
granules are discharged by exocytosis and kill the target cell.  Thus, 
killing tumour cells by using the immune system, particularly with 
CTLs, is a rational approach.
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Figure 10  A simplistic diagram to show the key players in the 
killing of  tumour cells by activated cytotoxic T lymphocytes.
(a) The antigenic peptide (as indicated in red) is loaded onto 
the MHC Class I molecule (as indicated in yellow) of the 
tumour cell which is presented to the T cell receptor. (b) 
Activated cytotoxic T lymphocytes release perforins and 
granzymes(as indicated by blue dots)  resulting in the  
death of the tumour cells by apoptosis.
The infusion of CTLs into cancer patients is known as adoptive 
cellular therapy.  Adoptive cellular therapy is also sometimes 
referred to as adoptive immunotherapy.  It involves taking cells from 
the patient, either from the blood or tumour, and manipulating these 
cells in the  laboratory. After in vitro manipulation, eg. stimulating 
them with cytokines or antigen, the cells are expanded to sufficient 
numbers and then infused back into the same patient.  
Since the last decade, the strategy of adoptive transfer of ex vivo 
generated tumour specific CD8+ effector T cells has been developed 
and utilized in either  alternative therapeutic intervention (for pre-
existing tumour eradication) or preventive vaccination, to create 
immunological protection against subsequent tumour challenge 
(Rosenberg SA, 2004). Progress was made with the infusion of 
autologous lymphokine-activated killer cells (Rosenberg et al., 
1985) and CD8+ T cell clones (Yee et al., 2002) as well as in 
improving methods for generating ex-vivo cytotoxic T cells with 
(a) (b)
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artificial antigen presenting cells (Maus et al., 2002) and genetic 
engineered T lymphocytes (Sadelain et al., 2003).  These attempts 
were made to improve the quantity, persistence and efficacy of 
adoptively transferred cytotoxic T lymphocytes. The preventive 
vaccinations, which involve the use of inactivated tumour cell 
injection and gene therapy with tumour-specific antigens, are 
effective in eliminating the inoculated tumour cells with the pre-
existing anti-tumour immunity (Chan et al.,  2002; Chan, 2010). 
Todate, the results show that these therapeutic approaches are 
relatively effective in most haemopoietic-derived tumours such as 
lymphoma (Rooney et al., 1998) but are less effective in established 
solid tumours such as nasopharyngeal carcinoma, which may largely 
be due to the existence of immune invasion mechanisms in the 
tumour microenvironment and the use of effector T cells that have 
heterogeneous properties.  
For nasopharyngeal carcinoma (NPC), immunotherapy 
may serve as either an alternative or an additional treatment to 
improve the clinical outcomes of the NPC patients as compared 
to conventional therapeutic approaches, namely radiotherapy and 
chemotherapy, which usually result in severe long lasting side 
effects. Various forms of immunotherapy strategies, both active 
and passive, are being developed and modified to treat NPC. 
The application of adoptive transfer of autologous cytotoxic T 
lymphocytes that recognize Epstein-Barr viral (EBV) proteins, 
namely, LMP-1, LMP-2 or EBNA-1, has been tested but with 
limited success (Lee et al., 1997).   Another approach using dendritic 
cells pulsed with peptides derived from LMP-2 (Chua et al., 2001) 
was used but again with limited success.  Several clinical trials have 
also been conducted  (Lin et al., 2002; Comoli et al., 2004; Comoli 
et al., 2005;  Ma & Chan, 2008; Merlo et al., 2008). The outcomes 
of these clinical trials are relatively inconsistent and unsatisfactory. 
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However, some promising outcomes have been shown in adoptive 
transfer of effector T cells that are specific for EBV antigens, 
including nuclear antigens (EBNA-1, -3A, -3B and -3C) and latent 
membrane proteins (LMP1 and LMP2), for the treatment of EBV 
associated lymphoproliferative diseases in transplant patients. 
Overall, some progress has been made in  adoptive T cell therapy 
in NPC and it has been shown to be relatively safe and capable 
of eliciting specific immune response to control the disease in 
advanced NPC (Comoli et al., 2005; Straathof et al., 2005).  The 
milestones in cancer immunotherapy and current trends indicating 
the usefulness of combining chemotherapy with adoptive cellular 
therapy have been clearly stated in a review (Leong and Seow, 2006).
It is still unclear whether the immune system can be harnessed 
for the purpose of immunotherapy.  The types of immune cells and 
phenotype optimal for killing tumour cells in vivo have not been 
definitely identified.   It is also unclear how tumours can tolerise the 
immune system and reduce antitumour immunity.  In the last decade, 
there has been a resurgence of studies on immunosuppression 
mediated by T regulatory cells.   The effectiveness of adoptive cell 
transfer to treat cancer patients requires a clear understanding of 
the functions of the cells in the tumour microenvironment.   We 
have detected the  presence of  cytokines (Chia et al., 2002) and 
infiltrating T regulatory cells in breast and nasopharyngeal tumours 
(Leong et al., 2006; Yip et al., 2009).  The  influence of cytokines 
and T regulatory cells on the success of adoptive cellular transfer 
of  ex-vivo activated CTLs  is still unknown.
Generation of  Cytotoxic CD8+  Lymphocytes Stimulated 
with LMP-2 Specific Peptides
When we commenced on this research, the conditions for generation 
of cells and phenotype of  in vitro generated cells for optimal 
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successful adoptive immunotherapy was not well characterized. 
Our research addressed the issue of the appropriate conditions to 
support growth and stimulate the generation of less differentiated 
effector cells with the ability to kill target tumour cells.  Latent 
membrane protein (LMP)-2 specific peptides were designed using 
the PEPVAC software.  However, the human leukocyte antigen 
(HLA) type of the lymphocytes present in peripheral blood of 
patients need to be determined first and HLA typing methods 
had to be established beforehand (Leong et al., 2010).  Finally 
the phenotype and cytotoxic capability of the cultured cells were 
successfully determined (manuscript in preparation).
This area of work posed a great challenge as generation of 
sufficient numbers of effector T cells was difficult.  Other challenges 
faced include the ability to sustain the persistence of these cells and 
to direct them to the tumour site.  These questions will need to be 
further addressed in future experiments to ensure the efficacy of 
the ex vivo activated T cells in killing tumour cells. 
IMMUNOMODULATORY EFFECTS OF MESENCHYMAL 
STEM CELLS
Mesenchymal stem cells (MSC) are multipotent non-hematopoietic 
stem cells, which reside in the bone marrow and other tissues, 
together with the hematopoietic stem cells (HSC) (Bobis et 
al., 2006). The multipotency of MSCs was first identified in 
1976 (Friedenstein et al., 1976) whereby, MSC in culture were 
demonstrated to have the ability to differentiate other cells such 
as osteocytes, chondrocytes and adipocytes.  Their potential 
application in regenerative medicine,  prevention of graft versus 
host reaction in transplants and anti-cancer therapy has recently 
generated a great deal of interest .
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Our study showed that MSCs derived from bone marrow, but 
not umbilical cord blood, inhibited T cell proliferation (Ramasamy 
et al., 2008; Tong et al., 2008). We also found that MSCs from 
human umbilical cord blood were capable of inhibiting the growth 
of K562, an undifferentiated erytholeukemia cell line derived from 
a chronic myeloid leukemia patient (manuscript in preparation). 
The procedure for generation of MSCs from human umbilical cord 
tissue was established in our laboratory (Tong et al., 2010). Further 
studies are currently underway to identify the factors responsible 
for tumour inhibitory activity.
DEVELOPMENT OF DIAGNOSTIC TESTS FOR 
DETECTION OF CANDIDA AND  
ASPERGILLUS FUMIGATUS
Introduction
In the last decade, the incidence of opportunistic fungal infections 
has increased dramatically.  An invasive, disseminated, life-
threatening form of candidiasis is seen in patients in intensive 
care as well as in post-surgical and neutropenic patients. The case 
fatality rate of systemic fungal infections, of 70% - 90%, is nearly 
three times higher than that for bacterial infections.  The Candida 
species of clinical importance reported at the University Hospital, 
University of Malaya, Kuala Lumpur ( Ng et al., 2000) differs from 
Western data whereby C.albicans represents 40 % of  systemic 
candidiasis.  Thus, the patterns of Candida prevalence in other 
hospitals in Malaysia is worthwhile investigating.  However, this 
requires accurate, rapid, sensitive and cost-effective diagnostic tests 
with the ability to detect many medically important Candida species. 
Current commercial diagnostic tests have a number of limitations 
including the inability to detect more than five Candida species, 
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being time consuming and in some cases, the tests are technically 
demanding. 
Early detection of systemic infection has a great impact on the 
clinical outcome of candidiasis.  The Candida species needs to be 
identified as some of the Candida species are inherently resistant 
to standard antifungal drugs.  For example,  C. krusei is resistant 
to fluconazole and  C. glabrata is resistant to fluconazole and 
itraconazole.  The wide spectrum antifungal drug, amphotericin has 
side effects.  Thus, it is important to identify the Candida species 
in order to prescribe the most suitable antifungal drug for the 
management of the patient.  Current laboratory diagnosis relies on 
blood culture, biochemical tests and morphological identification. 
These procedures take at least 3-7 days as the Candida is slow to 
grow and the tests are time-consuming and laborious.  Consequently, 
when these results are obtained, it is too late to save the life of the 
patient.   Thus, there is a dire need for development of improved 
rapid diagnostic tests.   
Summary of  Molecular Approaches and Monoclonal  
Antibody Production 
Successful detection was achieved by the use of seminested PCR 
utilizing ribosomal RNA (rRNA) region, successfully detecting and 
identifying sixteen fungi species; ten Candida species (C. albicans, 
C. dubliniensis, C. glabrata, C. guilliermondii, C. kefyr, C. krusei, 
C. lusitaniae, C. parapsilosis, C. rugosa and C. tropicalis), five 
Aspergillus species (A. flavus, A. fumigatus, A, nidulans, A. niger 
and A. terreus) and Cryptococcus neoformans (patent submitted). 
Besides rRNA, primers designed within the isocitrate lyase gene 
was designed for semi-nested and realtime PCR  to detect the ten 
Candida species.  In addition, monoclonal antibodies produced 
using in vivo mice method obtained from hybridoma clones, 
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designated as C6(3), F8(3) and F4(2) of  antibody isotype  IgG 
class and IgG2b  subclass, were generated. They  showed specificity 
towards Candida glabrata.  Five monoclonal antibodies were also 
generated for detection of Aspergillus fumigatus.
In conclusion, molecular diagnostic tests for ten species of 
Candida were successfully developed and monoclonal antibodies 
to Candida glabrata as well as Aspergillus fumigatus were also 
produced.  Further validation of these tests with clinical specimens 
will need to be performed.
PATENTS 
Title: Rapid semi-nested PCR method for  detection of 
ten medically important Candida species.
Inventors: Than L, Chong PP and Seow HF.
Applicant: Universiti Putra Malaysia 
Application 
No.:
PI2008 3143, PCT/MY2009/000109
Abstract: This invention relates to nucleic acid sequences 
used for detecting DNA from ten medically 
important Candida species by semi-nested PCR
Title: Nucleotide Probes for Detection and Species 
Differentiation of Candida Infections.
Inventors: Chong PP, Seow HF and Ng KP. 
Applicant: Universiti Putra Malaysia
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Abstract: This invention relates to nucleic acid sequences that 
were used for development of an array-based assay 
to detect DNA from eight medically important 
Candida species.
Title: D e t e c t i o n  o f  E p s t e i n - B a r r  Vi r u s  i n 
nasopharyngeal cancer
Inventors: Seow HF,  Yap YY and See HS.
Applicant: Universiti Putra Malaysia 
Application 
No.:
PI20071547
Abstract: This invention relates to novel primers used to 
quantify latent membrane protein-1 DNA  in 
peripheral blood of suspected nasopharyngeal 
carcinoma patients.
Title: Possible diagnostic markers as a guide to drug 
responsiveness in acute leukemia treatment
Inventors: Maha, Abdullah; Cheong, Soon Keng; Leong, Chui 
Fun, Seow, Heng Fong
Applicant: Universiti Putra Malaysia, filed Aug 2003.
Application 
No.: 
Abstract: Drug resistance is a major obstacle to successful 
treatment of acute myeloid leukaemia.  The precise 
molecular events involved in the  development 
of drug resistance remain largely unknown.  We 
found induction therapy induced  phosphorylation 
of mediators of  signaling  pathways.   Molecules
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of the PI3 kinase and MAP kinase pathways were 
found to increase or decrease phosphorylation 
depending on whether the cells were responding 
or resistant to chemotherapy.  PI3 kinase activates 
Akt which then phosphorylates FKHR and Bad. 
Sequestration of these latter two molecules leads to 
survival of the cell.  This was observed in cells that 
were found to be non-responsive to chemotherapy. 
In patients who achieved complete remission, p38 
and Jnk, members of the MAP kinase pathway, were 
found to be phosphorylated.  Observation of these 
changes suggests that these proteins may provide 
more specific targets for human therapeutic and 
diagnostic purposes.
Title: Peptides that inhibit the association of the 
surface and core antigens of hepatitis B virus. 
Inventors: Tan, W.S., Seow H.F., Yusoff, K. and Ho, K.L. 
Applicant: UPM. Filed on 28th September 2001. 
Application 
Number:
PI 20014538.
Abstract: This invention relates to recombinant phages that 
bind tightly to hepatitis B core particles and also 
peptides that inhibit the assembly of the hepatitis 
B virus.
Title: Immune response modulators and uses thereof
Inventors: Wood Paul and Seow Heng Fong
Applicant: Commonwealth Scientif ic and Research 
Organisation
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Application 
No.: 
WO1996AU00360 19960614
Abstract: The present invention relates to a nucleic acid 
molecule comprising a nucleotide sequence 
encoding or complementary to a sequence encoding 
an ovine IL-5 and IL-12 cytokine molecule.  The 
invention further provides recombinant isolated 
ovine IL-5 and IL-12 polypeptides which are 
useful as immune response modulators in livestock 
animals.
Title: Adjuvant
Inventors: Corner Leigh Austin, Rothel James Stuart, Wood 
Paul Richard, McWaters Peter and Seow Heng Fong
Applicant: Commonwealth Scientif ic and Research 
Organisation Australia
Application 
No.:
US19970732398 19970211
Abstract: The present invention relates generally to adjuvants 
which comprise a combination of at least two 
cytokines or functional derivatives thereof.  More 
particularly, the present invention is directed to an 
adjuvant such as a vaccine adjuvant comprising at 
least two cytokines or functional derivatives thereof 
wherein the cytokines selected from IL-1 beta and 
TNF alpha or IL-1 beta and GM-CSF.  The present 
invention is farther directed to genetic adjuvants 
encoding at least two cytokines or derivatives 
thereof, either separately of fused together.  
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The present invention also contemplates a method 
for enhancing an immune response to an antigen 
comprising the administration of at least two 
cytokines which act in synergy to enhance an 
immune response to said antigen.  The present 
invention is particularly useful in pharmaceutical 
vaccines and genetic vaccines in humans and 
livestock animals.
Title: Ovine Cytokine Genes
Inventors: Rothel James Stuart, Wood Paul Richard, Seow 
Heng Fong
Applicant: Commonwealth Scientif ic and Research 
Organisation Australia
Application 
no.:
WO1991AU00419 19910912
Abstract: The present invention relates to a nucleic acid 
molecule comprising a nucleotide sequence 
encoding or complementary to a sequence encoding 
of an ovine cytokine-like molecule.  The preferred 
cytokine-like molecules include recombinant IFN-
gamma, GM-CSF, IL=1, IL-2, IL-4, TNF alpha 
and TNF beta.
CONCLUSION
Our data on signal transduction revealed the heterogeneity of the 
individual specimens in terms of expression of the biomolecules. 
Nevertheless, correlation analysis conf irmed the positive 
relationship between pAkt and downstream targets such as pBAD 
and pGSK in colorectal cancer. In nasopharyngeal carcinoma, 
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results suggest that the PI3K/Akt/mTOR pathway is not a simple 
linear pathway.  Cytostatic and cell cycle arrest by a purified 
compound from a soil-derived Actinomycetes (genus Streptomyces) 
was demonstrated. The efficacy of the compound will need to be 
tested in animal models.
Similarly, the successful generation of cytotoxic CD8+ 
T lymphocytes  and mesenchymal stem cells for adoptive 
immunotherapy will require further experimentation in animal 
models.
In conclusion, the ‘magic bullets’ for cancer therapy that can be 
used to treat metastatic diseases and to overcome problems of drug 
resistance, toxicity and disease relapse are still at its infancy. Future 
studies on identification of feedback mechanisms and redundancies 
in the signalling network is essential for the formulation of multiple 
targeted drugs for  cancer treatment to overcome the problem of 
drug resistance.  This will require in depth understanding of how the 
complex signal transduction pathways and networks interact as well 
as the effects on the feedback mechanisms in the presence of one 
inhibitor or multiple inhibitors. Innovative strategies for effective 
design and delivery of cell-based therapies are highly desirable 
for treating cancer.  It is envisaged that in the next decade further 
advances will be made in the field of siRNA and tumour initiating 
cells,  sometimes referred to as ‘cancer stem cells’ research.
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